Hidden Cardiotoxicity of Rofecoxib Can be Revealed in Experimental Models of Ischemia/Reperfusion

Cardiac adverse effects are among the leading causes of the discontinuation of clinical trials and the withdrawal of drugs from the market. The novel concept of ‘hidden cardiotoxicity’ is defined as cardiotoxicity of a drug that manifests in the diseased (e.g. ischemic/reperfused), but n...

Descripció completa

Dades bibliogràfiques

Autors principals:	Gábor B. Brenner, András Makkos, Csilla Terézia Nagy, Zsófia Onódi, Nabil V. Sayour, Tamás G. Gergely, Bernadett Kiss, Anikó Görbe, Éva Sághy, Zoltán S. Zádori, Bernadette Lázár, Tamás Baranyai, Richárd S. Varga, Zoltán Husti, András Varró, László Tóthfalusi, Rainer Schulz, István Baczkó, Zoltán Giricz, Péter Ferdinandy
Format:	Artigo
Idioma:	Inglês
Publicat:	MDPI AG 2020-02-01
Col·lecció:	Cells
Matèries:	cardiotoxicity cox-2 electrophysiology safety testing arrhythmia vioxx ischemic conditioning reperfusion injury hiddentox pharmacovigilance
Accés en línia:	https://www.mdpi.com/2073-4409/9/3/551
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!